Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Immutep Limited
Immutep Limited News
Immutep Limited Quantitative Score
About Immutep Limited
Immutep Limited, a biotechnology company, engages in the research and development of pharmaceutical product candidates. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its lead product candidate is eftilagimod alpha (efti or IMP321), a recombinant protein that is in Phase IIb clinical trial as a chemoimmunotherapy combination for metastatic breast cancer. The company also develops TACTI-002, which is in a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer; TACTI-003 that is in Phase IIb clinical trial to treat HNSCC; and INSIGHT-004 and INSIGHT-003, which is in a Phase I clinical trial for the treatment of solid tumors, as well as INSIGHT-005 that is in Phase I/IIa clinical trial to treat solid tumors. Its other products include IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. Immutep Limited has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. Immutep Limited was incorporated in 1987 and is based in Sydney, Australia.
Immutep Limited Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
Immutep Limited Financials
Table Compare
Compare IMMP metrics with: | |||
|---|---|---|---|
Earnings & Growth | IMMP | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | IMMP | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | IMMP | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | IMMP | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Immutep Limited Income
Immutep Limited Balance Sheet
Immutep Limited Cash Flow
Immutep Limited Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Strong Buy |
| Return on Equity | Strong Sell |
| Return on Assets | Strong Sell |
| Debt/Equity Ratio | Buy |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Sell |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Historical Market Cap
Shares Outstanding
Immutep Limited Executives
| Name | Role |
|---|---|
| Mr. Marc Voigt | Chief Executive Officer, MD, Chief Financial Officer, Chief Business Officer & Executive Director |
| Dr. Frederic Triebel M.D., Ph.D. | Chief Scientific Officer & Executive Director |
| Ms. Deanne Miller LLB | Chief Operating Officer, General Counsel & Joint Company Secretary |
| Mr. Christian Mueller BBA, MSc. | Chief Development Officer |
| Mr. Stephan Winckels M.D., Ph.D. | Acting Chief Medical Officer |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Mr. Marc Voigt | Chief Executive Officer, MD, Chief Financial Officer, Chief Business Officer & Executive Director | Male | 1973 | 459.78K |
| Dr. Frederic Triebel M.D., Ph.D. | Chief Scientific Officer & Executive Director | 1955 | 385.34K | |
| Ms. Deanne Miller LLB | Chief Operating Officer, General Counsel & Joint Company Secretary | Female | 1977 | 273.39K |
| Mr. Christian Mueller BBA, MSc. | Chief Development Officer | Male | -- | |
| Mr. Stephan Winckels M.D., Ph.D. | Acting Chief Medical Officer | Male | -- |